← Back to Search

Monoclonal Antibody

JSP191 for MDS/AML

Phase 1
Waitlist Available
Led By Lori Muffly, MD,MS
Research Sponsored by Jasper Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year post donor cell transplant (28 days dose limiting toxicity period)
Awards & highlights

Summary

This trial is testing a new antibody conditioning regimen to see if it is safe and tolerable for people with Myelodysplastic Syndrome or Acute Myeloid Leukemia who are undergoing allogenic blood stem cell transplantation.

Eligible Conditions
  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year post donor cell transplant (28 days dose limiting toxicity period)
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year post donor cell transplant (28 days dose limiting toxicity period) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The number of dose limiting toxicities will be assessed.
The number of subjects experiencing adverse events and serious adverse events will be assessed.
The type of dose limiting toxicities will be assessed.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Blood Stem Cell Transplant w/ anti-CD117 conditioningExperimental Treatment1 Intervention
The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery. The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose.

Find a Location

Who is running the clinical trial?

Jasper Therapeutics, Inc.Lead Sponsor
4 Previous Clinical Trials
132 Total Patients Enrolled
Lori Muffly, MD,MSPrincipal InvestigatorStanford University
Andrew Artz, MD,MSPrincipal InvestigatorCity of Hope Medical Center

Media Library

JSP191 (Monoclonal Antibody) Clinical Trial Eligibility Overview. Trial Name: NCT04429191 — Phase 1
Myelodysplastic Syndrome Research Study Groups: Blood Stem Cell Transplant w/ anti-CD117 conditioning
Myelodysplastic Syndrome Clinical Trial 2023: JSP191 Highlights & Side Effects. Trial Name: NCT04429191 — Phase 1
JSP191 (Monoclonal Antibody) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04429191 — Phase 1
~8 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top